Levels of Endocan in Umbilical Cord Blood Samples of Pregnant Females With Intrauterine Growth Retardation

As a proteoglycan secreted from endothelial cells, expression, and secretion of endocan increases in the endothelium of several tissues secondary to inflammation. It can be regarded as an indicator of endothelial damage. Besides, it is both a target and a modulator of the vascular endothelial growth factor (VEGF) signaling pathway. Considering its action mechanisms, it can provide information about angiogenesis, inflammation, and vascular permeability.

It is known that intrauterine growth retardation mainly occurs as a result of endothelial dysfunction and abnormal angiogenesis in the placenta. In previous studies, maternal serum endocan levels have also been shown to be increased in cases of preeclampsia, which is mainly characterized by placental dysfunction.So, we hypothesize that there may be an association between endocan levels and intrauterine growth retardation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intrauterine Retardation Congenital, Hereditary, and Neonatal Diseases and Abnormalities Female Urogenital Diseases and Pregnancy Complications Fetal Diseases Fetal Growth Retardation Growth Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Pregnancy Complications Urogenital Diseases

Age range

18 year–35 year

Sex eligibility

Female

Study type

Observational

Primary location

Van Region Education and Training Hospital

Van, Turkey (Türkiye)

About this study

Endocan is a proteoglycan that is closely associated with inflammation. Its levels increase in association with the severity of endothelial damage. Endothelial dysfunction and abnormal angiogenesis in the placental tissues are the main pathophysiological mechanisms leading to intrauterine growth retardation.

It has been known that there was a significant association between maternal serum levels of endocan and preeclampsia. In cases with preeclampsia, increased serum levels of endocan in maternal blood samples has been reported.

Intrauterine growth retardation is a situation in which endothelial dysfunction and abnormal angiogenesis are the leading disturbances. In fetuses with intrauterine growth retardation, a hypoxic environment secondary to uteroplacental insufficiency. In previous studies, increased levels of endocan in maternal blood samples have been shown. Although maternal blood can be a good reflector of situations both in fetuses and their mothers, measurement of endocan in umbilical cord blood samples may better represent the pathology in fetuses.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For "intrauterine growth retardation" group:

consent to participate study
detection of intrauterine growth retardation during follow up of pregnancy

For "healthy fetuses" group:

consent to participate study
absence of intrauterine growth retardation during follow up of pregnancy

Exclusion criteria

multiple pregnancy
presence of major developmental anomalies of fetuses
detection of chromosomal anomalies
malnourished mothers
vegetarian diet of mothers
use of cigarette and alcohol during pregnancy
previous history of stillbirths

Treatment and study plan

endocan in umbilical cord blood

Diagnostic Test

After taking blood samples from the umbilical cord, centrifugation is applied to all samples for 15 minutes at 1000 rpm. The serum samples with specific identification numbers are going to be stored at -80 °C. After completing the study group, all serum samples will be analyzed using human endocan ELISA kit for the measurement of endocan levels.

Primary outcomes

endocan in umbilical cord blood

Time frame: just after delivery of fetus at clamping of umbilical cord

levels of endothelial cell specific molecule 1 (ng/ml) in umbilical cord blood

Sponsors and collaborators

Lead sponsor

Van Bölge Eğitim ve Araştırma Hastanesi

Other Gov

Registry information

Official study title

Comparison of Umbilical Cord Blood Levels of Endocan in Pregnant Females With and Without Intrauterine Growth Retardation

Important dates

Study start: 2020
Primary completion: 2020
Study completion: 2020
First posted: Nov 16, 2020
Registry last updated: Nov 16, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed